Biotech too slashes Covaxin rate, will cost states Rs 400/dose

Tribune Web Desk

Updated At : 12:42 PM Apr 30, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, April 29

After the Serum Institute of India cut the cost of Covid vaccine for state governments from Rs 400 to Rs 300, Bharat Biotech has slashed the price for states from Rs 600 a dose to Rs 400 a dose.

The indigenous Covaxin maker did not announce any concessions for private hospitals. The SII too had not reduced costs for private hospitals, which will have to procure their own vaccine doses from the manufacturers from May 1 when the adult inoculation drive begins. The SII is providing vaccines at Rs 600 a dose to private players and Bharat Biotech at Rs 1200 a dose. — TNS

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles